

in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicant's Attorney submits the following amendments, which add no new matter.

In the Claims

Amend Claims 7, 22 and 23 as shown below.

- 
- a1 7. (Amended) A method according to Claim [7] 6 wherein the pseudo-ligand is a peptide comprising the amino acid sequence lysine-glycine-lysine or lysine-glycine-alanine.
- 
22. (Amended) A method according to Claim 21 wherein the pseudo-ligand [or] is a biologically active fragment of nerve growth factor, or the pseudo-ligand is a nerve growth factor pseudo-ligand that binds to the p75 nerve growth factor receptor.
- a2 23. (Amended) A method according to Claim [23] 22 wherein the psuedo-ligand is a peptide comprising the amino acid sequence lysine-glycine-lycine or lysine-glycine-alanine.
- 

In the Specification

On page 1, line 5, between "1995" and the comma following it, insert ---(abandoned)---.

On page 1, line 7, between "8/31/94" and the period following it, insert ---(Patent No. 6,103,689)---.

On page 10, line 14, following "SEQ ID" within the parentheses, delete "Nos." and substitute therefor ---NO:10---.